December 5, 2014
Pfizer Inc. said on December 3 that its anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib) demonstrated superiority to standard chemotherapy as first-line treatment for ALK-positive advanced non-small cell lung cancer (NSCLC). In a global PIII study dubbed PROFILE 1014, Xalkori...read more